Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/28/2003CN1109537C Use of agonist substances of receptors associated with chlorine channel in treatment of wrinkles
05/28/2003CN1109499C Fungicide active substance combinations
05/27/2003US6570037 Reacting a primary amine derivative containing another secondary or tertiary amine with a nitrobenzene containing carbonyl halide group
05/27/2003US6570027 Method of preparing intermediates useful in synthesis of retroviral protease inhibitors
05/27/2003US6570020 Reacting 2-(3,3,3-trifluoropropyl),2-hydroxy,4a-benzyl-7-carboxy-1,2,3,4,4a,9,10,10a -octahydrophenanthrene with 2-methyl-3-(aminomethyl)pyridine to form the corresponding pyridyl-substituted amide at position 7
05/27/2003US6570013 (4-oxo-(5-trifluoromethyl-benzothiazol-2-ylmethyl)-3,4-dihydro -phthalazin-1-yl)-acetic acid ethanolamine salt, useful for treating diabetic complication in a mammal
05/27/2003US6570002 Inhibitor of programmed cell death
05/27/2003US6569992 Protein for use in the treatment of immunological, liver, reproductive and infectious disorders
05/27/2003US6569906 Composition containing a precursor capable of being hydrolysed by glucocerebrosidase
05/27/2003US6569905 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
05/27/2003US6569904 Via administration of toremifene for treatment or prevention of systemic/pulmonary hypertension, fibrosis, bronchial asthma, respiratory distress syndrome, myocardial infarction, thrombosis, congestive heart failure, and renal failure
05/27/2003US6569903 Ophthalmic compositions
05/27/2003US6569902 Inhibiting initiation or development of cancer by administering an effective dose of a nitrone free radical trapping agent to a subject
05/27/2003US6569900 Fulvic acid and its use in the treatment of various conditions
05/27/2003US6569897 Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors
05/27/2003US6569896 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer
05/27/2003US6569893 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
05/27/2003US6569890 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569889 Anticarcinogenic agents
05/27/2003US6569888 Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis
05/27/2003US6569887 (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
05/27/2003US6569886 Parasiticides
05/27/2003US6569885 Cyclic AMP-specific phosphodiesterase inhibitors
05/27/2003US6569883 Medicaments
05/27/2003US6569882 Viricides; enzyme inhibitors
05/27/2003US6569881 Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa
05/27/2003US6569879 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma; benzisoxazole compounds; e.g. ((5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy)acetic acid, methyl ester
05/27/2003US6569878 Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
05/27/2003US6569877 Benzimidazolyl phenyl anticancer agents
05/27/2003US6569872 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/27/2003US6569871 Substituted imidazole compounds
05/27/2003US6569870 Fluorinated quinolones as antimitotic and antitumor agents
05/27/2003US6569868 Imidazoly 2-indolinones as anticarcinogenic, -diabetic, -arthritic, -proliferative and inflammatory agents; fibrosis; autoimmune disorder, angiogenesis, restenosis, psoriasis, osteoarthritis and rheumatoid arthritis
05/27/2003US6569866 Sustained-release nalmefene preparations and method
05/27/2003US6569865 Psychological disorders; Alzheimer's disease
05/27/2003US6569864 1.75 mu M of acyclovir and 1 mu g/ml of fusaric acid; viricides
05/27/2003US6569863 Bicyclic heteroamatic compounds useful as LH agonists
05/27/2003US6569862 Methods for treatment of disorders of cardiac contractility
05/27/2003US6569861 Melanin concentrating hormone receptor ligands
05/27/2003US6569860 Alkoxycarbonylamino-heteroaryl carboxylic acid derivatives useful for treating the disorders of the urinary tract, pain, inflammation, respiratory states, edema formation, hypotensive vascular diseases, pain and allergies
05/27/2003US6569858 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo[3,4-c]carbazole and 12,13-(pyranosyl)-furo[3,4-c]indolo[2,3-a]carbazoles
05/27/2003US6569855 Particularly zinc metalloprotease activity for treatment of variety of maladies involving inflammation and/or tissue integrity
05/27/2003US6569853 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
05/27/2003US6569852 Coatings and soaks for medical prosthetic devices comprising taurinamide derivatives and carboxylic acids and/or salts thereof
05/27/2003US6569851 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
05/27/2003US6569850 Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tyrptophan and possibly a vitamin B12 compound
05/27/2003US6569849 N-Substituted azaheterocyclic compounds
05/27/2003US6569848 Compounds for the treatment of alzheimer's disease
05/27/2003US6569847 Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease
05/27/2003US6569846 Photodynamic therapy and diagnosis and in vitro photodynamic killing of viruses and microorganisms
05/27/2003US6569845 Angiogenesis inhibitors
05/27/2003US6569844 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives
05/27/2003US6569843 Administering antiprotozoa agents
05/27/2003US6569842 Method of preparing and use of prodrugs of betulinic acid derivatives
05/27/2003US6569840 Low-molecular heparin modification and remedy for skin ulcer
05/27/2003US6569838 Excising the keloid to create a wound, and administering bacterial polysaccharide exotoxin (cm101) to reduce scarring at a site of the wound
05/27/2003US6569837 β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B
05/27/2003US6569835 Hypolipidemics; treating obesity and disorders of lipid metabolism
05/27/2003US6569829 Removing impurities from a long chain N-acyl acidic amino acid such as N-lauroyl-L-glutamic acid containing an inorganic salt by solvent extraction using a solution of water and tert-butanol; use in cosmetics and detergents
05/27/2003US6569666 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
05/27/2003US6569649 Compositions and methods for saccharide synthesis
05/27/2003US6569638 Method for screening compounds for the treatment of neoplasia
05/27/2003US6569471 Administering water and/or fat-soluble cytosolic extract of pollen with Royal Jelly and Vitamin E to treat hormonal variations in fertile, peri- and post- menopausal women
05/27/2003US6569470 Monoamine oxidase (MAO) inhibitors and uses thereof
05/27/2003US6569463 Encapsulation coat includes different combinations of pharmaceutical active ingredients, hydrophilic and lipophilic surfactants, and triglycerides
05/27/2003US6569460 Film-coated tablet for improved upper gastrointestinal tract safety
05/27/2003US6569457 Enteric coated pharmaceutical tablet and method of manufacturing
05/27/2003US6569456 Angiotensin converting enzyme (ACE) inhibitor; controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat; pharmacokinetics; easier to swallow; treating hypertension
05/27/2003US6569455 Quick-release extrudates, method for preparing the same and compositions obtained from said extrudates
05/27/2003US6569453 No enteric layers and are suitable for oral administration
05/27/2003US6569452 Camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethylene glycol; irinotecan hydrochloride
05/27/2003US6569450 Lipid-conjugated polyamide compounds and related compositions and methods thereof
05/27/2003US6569449 For treatment of eating disorders, narcotic dependence and alcoholism.
05/27/2003US6569448 Method for preventing crystal formation in a dispersion of a liquid in a matrix
05/27/2003US6569446 Solubilization of flavonols
05/27/2003US6569443 Topical treatment or prevention of ocular infections
05/27/2003US6569441 Therapeutic inhibitor of vascular smooth muscle cells
05/27/2003US6569437 Skin disorders
05/27/2003US6569429 Isolated polypeptide comprising the amino acid residues 1 to 344 of (SEQ ID NO: 2); systemic lupus erythematosus; pulmonary disease or disorder
05/27/2003US6569417 Delivering biocompatible polymer, biocompatible solvent, and contrast agent to periurethral tissue of mammal wherein delivery is conducted under conditions such that polymer precipitate forms in situ in tissue
05/27/2003US6569416 Compositions containing synthetic soil-extract materials and medicaments based thereon
05/27/2003US6569414 Panthenol and nicotinic acid amide; lipid-soluble ester alcohol or ester polyol by reacting an epoxy fatty acid ester with a mono- or polyhydric alcohol
05/27/2003US6569152 Sustained release delivery systems for solutes
05/27/2003US6569075 Lipoxin compounds and their use in treating cell proliferative disorders
05/27/2003CA2412624A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurogenerative diseases
05/27/2003CA2412466A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
05/27/2003CA2387361C Crystal form 0 and form ii of clarithromycin and uses thereof
05/27/2003CA2387356C Crystal form 0 and form i of clarithromycin and uses thereof
05/27/2003CA2386534C Crystal form ii of clarithromycin and uses thereof
05/27/2003CA2386527C Crystal form i of clarithromycin
05/27/2003CA2321829C Topical composition containing human epidermal growth factor
05/27/2003CA2310960C Phosphate-binding polymers for oral administration
05/27/2003CA2277274C Crystal form 0 of clarithromycin
05/27/2003CA2268847C Substituted oximes derivatives useful as neurokinin antagonists
05/27/2003CA2268438C Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
05/27/2003CA2258606C Crystal form ii of clarithromycin
05/27/2003CA2231558C .gamma.-rar antagonist ligand or .alpha.-rar agonist ligand as an apoptosis inhibitor
05/27/2003CA2213054C Novel bis(imido) derivatives, a process for their preparation and pharmaceutical compositions containing them
05/27/2003CA2209391C New heterocyclic biaryl compounds and their use in human or veterinary medicine and in cosmetics
05/27/2003CA2199747C 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
1 ... 5457 5458 5459 5460 5461 5462 5463 5464 5465 5466 5467 5468 5469 5470 5471 5472 5473 5474 5475 5476 5477 ... 7860